Ji Yeon Kang1, Su Jin Jang2, Won Woo Lee3, Sung June Jang1, Yun Jong Lee4, Sang Eun Kim3. 1. Department of Nuclear Medicine, Seoul National University Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707 Korea. 2. Department of Nuclear Medicine, Seoul National University Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707 Korea ; Department of Nuclear Medicine, CHA Bundang Medical Center, CHA University College of Medicine, Seoul, Korea. 3. Department of Nuclear Medicine, Seoul National University Bundang Hospital, 166 Gumi-ro, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-707 Korea ; Institute of Radiation Medicine, Medical Research Center, Seoul National University, Seoul, South Korea. 4. Department of Internal Medicine, Seoul National University College of Medicine, Seoul, South Korea.
Abstract
PURPOSE: Salivary gland scintigraphy (SGS) provides an objective means of diagnosing salivary gland dysfunction in Sjögren's syndrome (SS) patients and in thyroid cancer patients after radioactive iodine (RAI) therapy. In the present study, SGS was performed in SS patients and in thyroid cancer patients post-RAI, and scintigraphic parameters were compared. METHODS: Twenty-eight SS patients (males:females = 1:27, age 53.3 ± 11.9 years), 28 controls (males:females = 3:25, age 54.1 ± 10.1 years), and 92 thyroid cancer patients (males:females = 28:64, age 46.2 ± 12.9) who had undergone a session of high-dose RAI therapy (mean dose, 5.2 ± 1.5 GBq) were included. SGS was performed using Tc-99m pertechnetate (925 MBq). Scintigraphic parameters (parotid uptake ratio PU, submandibular uptake ratio SU, percentage parotid excretion %PE, and percentage submandibular excretion %SE) were measured and compared for SS, thyroid cancer post-RAI, and control patients. RESULTS: PU, SU, %SE, and %PE were all significantly lower in SS than in post-RAI thyroid cancer or control patients (p < 0.05), whereas only %PE was significantly lower in post-RAI thyroid cancer patients than in controls (p < 0.05). SU and %SE were found to be correlated with the unstimulated whole salivary flow rate. CONCLUSION: Scintigraphic parameters derived from SGS can play a crucial role in the detection of salivary gland dysfunction in SS patients and in post-RAI thyroid cancer patients.
PURPOSE: Salivary gland scintigraphy (SGS) provides an objective means of diagnosing salivary gland dysfunction in Sjögren's syndrome (SS) patients and in thyroid cancerpatients after radioactive iodine (RAI) therapy. In the present study, SGS was performed in SS patients and in thyroid cancerpatients post-RAI, and scintigraphic parameters were compared. METHODS: Twenty-eight SS patients (males:females = 1:27, age 53.3 ± 11.9 years), 28 controls (males:females = 3:25, age 54.1 ± 10.1 years), and 92 thyroid cancerpatients (males:females = 28:64, age 46.2 ± 12.9) who had undergone a session of high-dose RAI therapy (mean dose, 5.2 ± 1.5 GBq) were included. SGS was performed using Tc-99m pertechnetate (925 MBq). Scintigraphic parameters (parotid uptake ratio PU, submandibular uptake ratio SU, percentage parotid excretion %PE, and percentage submandibular excretion %SE) were measured and compared for SS, thyroid cancer post-RAI, and control patients. RESULTS:PU, SU, %SE, and %PE were all significantly lower in SS than in post-RAI thyroid cancer or control patients (p < 0.05), whereas only %PE was significantly lower in post-RAI thyroid cancerpatients than in controls (p < 0.05). SU and %SE were found to be correlated with the unstimulated whole salivary flow rate. CONCLUSION: Scintigraphic parameters derived from SGS can play a crucial role in the detection of salivary gland dysfunction in SS patients and in post-RAI thyroid cancerpatients.
Authors: C Vitali; S Bombardieri; R Jonsson; H M Moutsopoulos; E L Alexander; S E Carsons; T E Daniels; P C Fox; R I Fox; S S Kassan; S R Pillemer; N Talal; M H Weisman Journal: Ann Rheum Dis Date: 2002-06 Impact factor: 19.103
Authors: G L Schall; L G Anderson; R O Wolf; J R Herdt; T M Tarpley; N A Cummings; L S Zeiger; N Talal Journal: JAMA Date: 1971-06-28 Impact factor: 56.272
Authors: R A Valdés Olmos; R B Keus; R P Takes; H van Tinteren; G Baris; F J Hilgers; C A Hoefnagel; A J Balm Journal: Cancer Date: 1994-06-15 Impact factor: 6.860